Clinically diverse, psoriasis is a chronic skin condition that can manifest as plaque, flexural, guttate, psoriatic arthritis, nail psoriasis, pustular, or erythrodermic. Psoriasis is thought to impact 60 million individuals globally, and in the UK, it affects 1.52% of the general population. Psoriasis is an inflammatory disease that is mediated by the immune system and has a significant hereditary component. A comprehensive and multidisciplinary approach to therapy is necessary due to its correlation with psoriatic arthritis and elevated incidence of cardiometabolic, hepatic, and psychiatric comorbidities. Topical treatments for psoriasis include corticosteroids and vitamin D analogs; phototherapy (such as psoralen and ultraviolet A radiation (PUVA) and narrowband ultraviolet B radiation (NB-UVB); standard systemic treatments (such as methotrexate, ciclosporin, and acitretin); biologic treatments (such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 inhibitors); and small molecule inhibitors (such as dimethyl fumarate and apremilast).Advance in the understanding of its pathophysiology have led to development of highly effective and targeted treatment.